Hyperphosphorylated tau protein in the cerebrospinal fluid of patients with Alzheimer's disease and other dementias: Preliminary findings

Arquivos de Neuro-Psiquiatria

Volumn 62, Issue 3 B, 2004, Pages 751-755

  Hartmann, Ana Paula Barbosa Jeronimo ^a,c   De Almeida, Sérgio Monteiro ^b   Livramento, José Antonio ^a   Nitrini, Ricardo ^a   Takahashi, Daniel ^a   Caramelli, Paulo ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Department of Cell Biology   (Brazil)

^c Federal University of Curitiba PR ^*  (Brazil)

Author keywords

Alzheimer's disease; Cerebrospinal fluid; Differential diagnosis; Tau protein

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; PHOSPHOPROTEIN; PHOSPHOTAU PROTEIN; TAU PROTEIN; THREONINE; UNCLASSIFIED DRUG;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN TISSUE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; COMPARATIVE STUDY; DEMENTIA; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DISEASE DURATION; DISEASE SEVERITY; EARLY DIAGNOSIS; FEMALE; HUMAN; MALE; MINI MENTAL STATE EXAMINATION; NEUROFIBRILLARY TANGLE; ONSET AGE; PRESENILE DEMENTIA; PROTEIN HYPERPHOSPHORYLATION; PROTEIN PHOSPHORYLATION; SCORING SYSTEM; SENILE DEMENTIA; SENILE PLAQUE;

EID: 5444233547     PISSN: 0004282X     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0004-282X2004000500001     Document Type: Article

References (30)

1. Herrera E Jr, Caramelli P, Silveira AS, Nitrini R. Epidemiologic survey of dementia in a community-dwelling Brazilian population. Alzheimer Dis Assoc Disord 2002;16:103-108.
2. Mirra SS, Heyman A, McKeel D et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD): part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991;41:479-486.
3. Wisniewski HM, Robe A, Zigman W, Silverman W. Neuropathological diagnosis of Alzheimer disease. J Neuropathol Exp Neurol 1989;48:606-609.
4. Arai H, Clark CM, Ewbank DC, et al. Cerebrospinal fluid tau protein as a potential diagnostic marker in Alzheimer's disease. Neurobiol Aging 1998;19:125-126.
5. Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol 1995;26:231-245.
6. Galasko D, Hansen L Vigo-Pelfrey C, et al. Antemortem CSF tau is related to neuronal pathology at autopsy in Alzheimer's disease. Soc Neurosci Abstr 1995;581.
7. Bramblett GT, Goedert M, Jakes R, Merrick SE, Trojanowski JQ, Lee VM. Abnormal tau phosphorylation at Ser396 in Alzheimer's disease recapitulates development and contributes to reduced microtubule binding. Neuron 1993;10:1089-1099.
8. Vigo-Pelfrey C, Seubert P, Barbour R, et al. Elevation of microtubule-associated protein tau in the cerebrospinal fluid of patients with Alzheimer's disease. Neurology 1995;45:788-793.
9. Consensus report of the Working Group on: "Molecular and Biochemical Markers of Alzheimer's Disease". The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group. Neurobiol Aging 1998;19:109-116.
10. Andreasen N, Minthon L, Vanmechelen E, et al. Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment. Neurosci Lett 1999;273:5-8.
11. Andreasen N, Vanmechelen E, Vanderstichele H, et al. Cerebrospinal fluid levels of total-tau, phospho-tau and AB42 predicts development of Alzheimer's disease in patients with mild cognitive impairment. Acta Neurol Scand. 2003;179:(Suppl)47-51.
12. Hu YY, He SS, Wang XC, et al. Elevated levels of phosphorylated neurofilament proteins in cerebrospinal fluid of Alzheimer disease patients. Neurosci Lett 2002;320:156-160.
13. Shoji M, Matsubara E, Kanai M, et al. Combination assay of CSF tau, A beta 1-40 and A beta 1-42(43) as a biochemical marker of Alzheimer's disease. J Neurol Sci 1998;158:134-140.
14. Sunderland T, Linker G, Mirza N, et al. Decreased B-amyloid and increased tau levels in cerebrospinal fluid of patients with Alzheimer's disease. JAMA 2003;289:2094-2103.
15. Kanai M, Matsubara E, Isoe K, et al. Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: a study in Japan. Ann Neurol 1998;44:17-26.
16. Kapaki E, Kilidireas K, Paraskevas GP, Michalopoulou M, Patsouris E. Highly increased CSF tau protein and decreased beta-amyloid (1-42) in sporadic CJD: a discrimination from Alzheimer's disease? J Neurol Neurosurg Psychiatry 2001;71:401-403.
17. Riemenschneider M, Wagenpfeil S, Diehl J, et al. Tau and Abeta42 protein in CSF of patients with frontotemporal degeneration. Neurology 2002;58:1622-1628.
18. Vandermeeren M, Mercken M, Vanmechelen E, et al. Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J Neurochem 1993;61:1828-1834.
19. Ishiguro K, Ohno H Arai H, et al. Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer's disease. Neurosci Lett 1999;270:91-94.
20. Vanmechelen E, Van Kerschaver E, Blennow K, et al. CSF-phosphotau (181P) as a promising marker for discriminating Alzheimer's disease from dementia with Lewy bodies. In Iqbal K, Sisodia SS, Winblad B (eds). Alzheimer's disease: advances in ethiology pathogenesis and therapeutics. Chichester: John Willey Sons; 2001:285-291.
21. Parnetti L, Lanari A, Amici S, Gallai V, Vanmechelen E, Hulstaert F. CSF phosphorylated tau is a possible marker for discriminating Alzheimer's disease from dementia with Lewy bodies. Phospho-Tau International Study Group. Neurol Sci 2001;22:77-78.
22. Kopke E, Tung YC, Shaikh S, Alonso AC, Iqbal K, Grundke-Iqbal I. Microtubule-associated protein tau: abnormal phosphorylation of a non- paired helical filament pool in Alzheimer disease. J Biol Chem 1993;268:24374-24384.
23. Sjogren M, Davidsson P, Tullberg M, et al. Both total and phosphorylated tau are increased in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2001;70:624-360.
24. Vanmechelen E, Vanderstichele H, Davidsson P, et al. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett 2000;285:49-52.
25. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADR-DA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
26. Clinical and neuropathological criteria for frontotemporal dementia. The Lund and Manchester Groups. J Neurol Neurosurg Psychiatry 1994;57:416-418.
27. Erkinjuntti T. Clinical criteria for vascular dementia: the NINDS-AIREN criteria. Dementia 1994;5:189-192.
28. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996;47:1113-1124.
29. Mesulam M, Mesulam M. Clinical Neurology. International practice and research: unusual dementias. Guest Edition. MN Rossor, 1992.
30. Buerger K, Teipel SJ, Zinkowski R, et al. CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects. Neurology 2002;59:627-629.